<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817150</url>
  </required_header>
  <id_info>
    <org_study_id>LARC1</org_study_id>
    <nct_id>NCT04817150</nct_id>
  </id_info>
  <brief_title>3D vs 2D-laparoscopy for Rectocele and Rectal Prolapse Correction: a Prospective, Randomized, Single Center Study</brief_title>
  <acronym>LARC</acronym>
  <official_title>LARC Study: Three-dimensional Versus Conventional 2D-laparoscopy for Rectocele and Rectal Prolapse Repair: a Prospective, Randomized, Single Center Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexander Khitaryan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Private Healthcare Institution Clinical Hospital RGD-Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to compare proximate and remote results of 3D and conventional 2D laparoscopic&#xD;
      interventions in terms of efficacy and safety in treatment of symptomatic rectocele and&#xD;
      rectal prolapse.&#xD;
&#xD;
      This is a prospective randomized comparative study in parallel groups conducted in single&#xD;
      Colorectal unit. Inclusion criteria: female patients with stage 3 rectocele (3-4 POP-Q&#xD;
      [pelvic organ prolapse quantification] grade) and/or full-thickness rectal prolapse.&#xD;
&#xD;
      Intervention - laparoscopic ventral rectopexy. The primary outcome is objective cure rate of&#xD;
      pelvic prolapse. Secondary outcomes include obstructive defecation and incontinence symptoms&#xD;
      according to Wexner and Cleveland Clinic scales, and satisfaction according to Patient Global&#xD;
      Impression of Improvement questionnaire. Operative times, intraoperative blood loss, length&#xD;
      of hospital stay, postop pain severity, urinary incontinence, as well as surgical and mesh&#xD;
      complications are also assessed.&#xD;
&#xD;
      The specific point of interest in this study is surgeon's tiredness after the operation&#xD;
      assessed with Profile of Mood States questionnaire.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a prospective randomized comparative study in parallel groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Outcomes are assessed by 2 independent blinded coloproctologists</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>objective cure rate</measure>
    <time_frame>12 months postop</time_frame>
    <description>objective cure rate according to clinical POP-Q assesment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>obstructive defecation cure</measure>
    <time_frame>12 months postop</time_frame>
    <description>according to Wexner scale score (Cleveland Clinic Constipation Scoring System, scale of 0-30, with 0 = minimum, healthy individual and 30 = maximum, severe obstructive defecation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incontinence cure</measure>
    <time_frame>12 months postop</time_frame>
    <description>according to Cleveland Clinic scale score (Cleveland Clinic Incontinence Scoring System, scale of 0-20, with 0 = minimum, perfect continence and 20 = maximum, complete incontinence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient's satisfaction</measure>
    <time_frame>12 months postop</time_frame>
    <description>according to PGII (Patient Global Impression of Improvement) questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>intraoperative blood loss</measure>
    <time_frame>intraoperatively</time_frame>
    <description>intraoperative blood loss (ml)</description>
  </other_outcome>
  <other_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>length of hospital stay (days)</description>
  </other_outcome>
  <other_outcome>
    <measure>postop pain severity</measure>
    <time_frame>24 hours postop</time_frame>
    <description>VAS (Visual Analog Scale)</description>
  </other_outcome>
  <other_outcome>
    <measure>postop stress urinary incontinence</measure>
    <time_frame>12 months</time_frame>
    <description>Valsalva test (positive - urinary incontinence presents, negative - no stress urinary incontinence)</description>
  </other_outcome>
  <other_outcome>
    <measure>complications rate</measure>
    <time_frame>12 months</time_frame>
    <description>early and remote complications</description>
  </other_outcome>
  <other_outcome>
    <measure>surgeon's tiredness</measure>
    <time_frame>1 hour after the surgery</time_frame>
    <description>Profile of Mood States Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>postoperative seroma/hematoma volume</measure>
    <time_frame>3 weeks</time_frame>
    <description>size of liquid cavity surrounding mesh on 2-3 postoperative day and on 2-3 postoperative week (ml)</description>
  </other_outcome>
  <other_outcome>
    <measure>postop pain syndrom duration</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>pain medications consumption</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rectocele; Female</condition>
  <condition>Rectocele and Incomplete Uterine Prolapse</condition>
  <condition>Rectocele and Complete Uterovaginal Prolapse</condition>
  <condition>Rectal Prolapse</condition>
  <arm_group>
    <arm_group_label>3D-laparoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who underwent 3D laparoscopic ventral rectopexy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2D-laparoscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients who underwent conventional 2D laparoscopic ventral rectopexy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic ventral mesh rectopexy</intervention_name>
    <description>Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore</description>
    <arm_group_label>2D-laparoscopy</arm_group_label>
    <arm_group_label>3D-laparoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  stage 3 rectocele (3-4 POP-Q grade) and/or full-thickness rectal prolapse&#xD;
&#xD;
          -  age 18-70 y.o.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe concomitants chronic diseases (American Society of Anesthesiologists class III&#xD;
             - IV),&#xD;
&#xD;
          -  ongoing oncological diseases,&#xD;
&#xD;
          -  ongoing hematological diseases,&#xD;
&#xD;
          -  ongoing inflammatory diseases of the colon and pelvic organs,&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anastasiya Golovina</last_name>
    <phone>+79518319720</phone>
    <email>a_anastacia@icloud.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Private Healthcare Institution Clinical Hospital &quot;RGD-Medicine&quot; Rostov-on-Don&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastasiya Golovina, Dr</last_name>
      <phone>+79518319720</phone>
      <email>a_anastacia@icloud.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Private Healthcare Institution Clinical Hospital RGD-Medicine</investigator_affiliation>
    <investigator_full_name>Alexander Khitaryan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Prolapse</mesh_term>
    <mesh_term>Rectocele</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

